Patents Examined by Mark Navarro
-
Patent number: 7803357Abstract: Various medical conditions, some previously treated by injection or surgery, are effectively treated by a topical application of a composition of urea and a chemotherapeutic agent. Such agents include sclerosing agents, vasodilators, botulinum toxin and minoxidil. Conditions as diverse as spider veins, erectile dysfunction, facial wrinkles, hair loss and baldness can be effectively treated with the compositions.Type: GrantFiled: November 3, 2008Date of Patent: September 28, 2010Inventor: John V Cappello
-
Patent number: 7795402Abstract: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody is enriched for immunoglobulins having both an antigen-binding portion that binds a Staphylococcus aureus capsular polysaccharide antigen and a constant region that does not bind staphylococcal protein A.Type: GrantFiled: July 2, 2009Date of Patent: September 14, 2010Assignee: STROX Biopharmaceuticals, LLCInventor: Stanley Arthur Kim
-
Patent number: 7794969Abstract: The present disclosure identifies methods and compositions for modifying photoautotrophic organisms as hosts, such that the organisms efficiently convert carbon dioxide and light into n-alkanes, and in particular the use of such organisms for the commercial production of n-alkanes and related molecules.Type: GrantFiled: April 13, 2010Date of Patent: September 14, 2010Assignee: Joule Unlimited, Inc.Inventors: Nikos Basil Reppas, Christian Perry Ridley
-
Patent number: 7794938Abstract: Described are kits and methods useful for detection of seven agricultural pathogens (BPSV; BHV; BVD; FMDV; BTV; SVD; and VESV) in a sample. Genomic sequence information from 7 agricultural pathogens was analyzed to identify signature sequences, e.g., polynucleotide sequences useful for confirming the presence or absence of a pathogen in a sample. Primer and probe sets were designed and optimized for use in a PCR based, multiplexed Luminex assay to successfully identify the presence or absence of pathogens in a sample.Type: GrantFiled: January 12, 2007Date of Patent: September 14, 2010Assignee: Lawrence Livermore National Security, LLCInventors: Mary Teresa McBride, Thomas Richard Slezak, Sharon Lee Messenger
-
Patent number: 7790412Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: May 11, 2007Date of Patent: September 7, 2010Assignee: Sanofi Pasteur Limited/Sanofi Pasteur LimitéeInventors: Lynn Doucette-Stamm, David Bush, Qiandong Zeng, Timothy Opperman, Chad Eric Houseweart
-
Patent number: 7786255Abstract: The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Some antibodies of the invention enhance opsonophagocytic killing and in vivo protection against bacteria that express PNAG such as but not limited to Staphylococci and E. coli. Compositions of these peptides, including pharmaceutical compositions, are also provided, as are functionally equivalent variants of such peptides.Type: GrantFiled: April 21, 2005Date of Patent: August 31, 2010Assignees: The Bringham and Women's Hospital, Inc., Beth Israel Deaconess Medical Center, Inc.Inventors: Gerald B. Pier, Casie Anne Kelly-Quintos, Lisa Cavacini, Marshall R. Posner
-
Patent number: 7785592Abstract: The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.Type: GrantFiled: October 1, 2007Date of Patent: August 31, 2010Assignee: MedImmune, LLCInventors: Cynthia N. Oliver, Erica Shane, Benjamin S. Isaacs, Christian B. Allan, Stephen T. Chang
-
Patent number: 7786286Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 16, 2006Date of Patent: August 31, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josée Hamel, Clement Rioux
-
Patent number: 7776335Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: August 17, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7763434Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R?-subunit and that are incapable of transducing a signal through either the ?- or ?-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the ?- or ?-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.Type: GrantFiled: May 23, 2007Date of Patent: July 27, 2010Assignee: Immunex CorporationInventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
-
Patent number: 7759070Abstract: A conserved inner-core oligosaccharide epitope expressed on the lipopolysaccharide (LPS) of a range of disease causing pathogenic bacterial isolates, including Actinobacillus pleuropneumoniae (Ap), Mannheimia haemolytica (Mh) and Pasteurella multocida (Pm), is disclosed. Construction of a mutant bacterial strain exclusively expressing the conserved inner core OS epitope as a terminally exposed structure has allowed the identification, production and isolation of an inner core LPS which is common to all three organisms. Further provided are associated vaccines, antibodies raised against the conserved LPS inner core and glycoconjugates comprising the LPS inner core linked to an immunogenic carrier.Type: GrantFiled: May 16, 2005Date of Patent: July 20, 2010Assignee: National Research Council of CanadaInventors: Andrew D. Cox, James C. Richards
-
Patent number: 7754868Abstract: Stress-related nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, stress-related fusion proteins, antigenic peptides, and anti-stress-related antibodies are encompassed. The invention also provides recombinant expression vectors containing a nucleic acid molecule of the invention and cells into which the expression vectors have been introduced. Methods for producing the polypeptides and methods of use for the polypeptides of the invention are further disclosed.Type: GrantFiled: March 11, 2008Date of Patent: July 13, 2010Assignee: North Carolina State UniversityInventors: Todd R. Klaenhammer, William M. Russell, Eric Altermann, Andrea Azcarate-Peril
-
Patent number: 7754218Abstract: To improve the stability of vaccines comprising aluminum salt(s), the invention uses the amino acid histidine. This can improve pH stability and adjuvant adsorption and can reduce antigen hydrolysis. Histidine is preferably present during adsorption to the aluminum salt(s). The antigen in the vaccine may be a protein or a saccharide and is preferably from N. meningitidis.Type: GrantFiled: January 3, 2008Date of Patent: July 13, 2010Assignee: Novartis Caccines and Diagnostics SRLInventors: Mario Contorni, Massimo Maffei
-
Patent number: 7749499Abstract: The identification of a highly conserved, immunologically accessible antigen at the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to Proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoeae strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: July 6, 2010Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7749705Abstract: Apparatus and methods are described for detecting target DNA in a biological sample using capture probes and electrically-assisted hybridization. The reaction cell is formed with an attachment surface of aluminum oxide for better thermal and physical properties, and the aluminum oxide surface is coated with anti-DIG antibody to provide a convenient attachment layer for the capture probes allowing their correct orientation, while the capture probes are formed with a DIG-label so that they attach to the surface of the cell through an anti-DIG/DIG linkage.Type: GrantFiled: November 15, 2006Date of Patent: July 6, 2010Assignee: Hai Kang Life Corporation LimitedInventors: Cheung Hoi Yu, Lok-Ting Lau, Selma Sau Wah Lin, Duncan Ka-Yun Chan
-
Patent number: 7745580Abstract: The present invention relates to nucleic acid molecules related to the var2csa gene family as well as amino acid sequences encoded by such nucleic acid molecules with respect to their role in mediating adhesion of infected red blood cells to chondroitin sulphate A (CSA) in the placenta which is characteristic for the pathogenesis of pregnancy associated malaria (PAM). Accordingly, The invention provides the use compounds that are related to VAR2CSA polypeptides var2csa nucleic acid molecules as medicaments, as well as it provides pharmaceutical compositions, in particular immunological compositions and vaccines, hereunder nucleotide-based vaccines comprising these compounds. In addition, the invention provides the use of the compounds mentioned for the manufacture of compositions, such as immunogenic compositions.Type: GrantFiled: December 30, 2003Date of Patent: June 29, 2010Assignee: Kobenhavns UniversitetInventors: Thor Grundtvig Theander, Ali Salanti, Lars Hviid, Trine Staalsø, Anja Tatiana Ramstedt Jensen, Thomas Lavstsen, Madelaine Dahlbäck
-
Patent number: 7745172Abstract: A method for producing an ?-L-aspartyl-L-phenylalanine-?-ester (also named ?-L-(?-o-substituted aspartyl)-L-phenylalanine), which is an intermediate of an ?-L-aspartyl-L-phenylalanine-?-methyl ester (also named ?-L-aspartyl-L-phenylalanine methyl ester; product name: aspartame), easily, at high yield and inexpensively without going through a complex synthesis method is provided. Further, an easy, inexpensive and high-yield production method for an ?-L-aspartyl-L-phenylalanine-?-methyl ester is provided. ?-L-aspartyl-L-phenylalanine-?-methyl ester is produced from a L-aspartic acid-?,?-diester and L-phenylalanine using an enzyme or enzyme-containing substance that has an ability to catalyze a reaction in which L-phenylalanine performs no nucleophilic attack on a ?-ester site of L-aspartic acid-?,?-diester but performs a nucleophilic attack on an ?-ester site thereof.Type: GrantFiled: January 7, 2008Date of Patent: June 29, 2010Assignee: Ajinomoto Co., Inc.Inventors: Kenzo Yokozeki, Ayako Ohno, Seiichi Hara, Isao Abe
-
Patent number: 7741297Abstract: Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and/or non-immunological agents. Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer than eight nucleotides, and lipidated oligonucleotides comprising a plurality of CpG dinucleotide-containing segments connected by a long internucleoside linkage are of particular interest. These compounds are also novel per se.Type: GrantFiled: February 4, 2003Date of Patent: June 22, 2010Assignee: Oncothyreon Inc.Inventors: Zi-Hua Jiang, Rao Koganty, Damayanthi Yalamati, Myung-Gi Baek
-
Patent number: 7736859Abstract: The invention relates to a method for detecting an infection of a mammal with an acid-resistant microorganism, wherein (a) a stool sample of a mammal is incubated with at least two different monoclonal antibodies, fragments or derivatives thereof or aptamers under conditions allowing a complex formation of antigens of the acid-resistant microorganism with antibodies, fragments or derivatives thereof or the aptamers, and wherein (aa) the first monoclonal antibody or the fragment or the derivative thereof or the first aptamer specifically binds an epitope of the first antigen, which shows at least with some mammals a structure after the intestinal passage that corresponds to the native structure or the structure which a mammal produces antibodies against after being infected or immunised with the acid-resistant microorganism or an extract or lysate thereof or a protein therefrom or a fragment thereof or a synthetic peptide; (ab) the second monoclonal antibody or the fragment or the derivative thereof or the secType: GrantFiled: August 31, 2006Date of Patent: June 15, 2010Assignee: Oxoid (ELY) LimitedInventors: Christian Reiter, Gerhard Cullman, Ulrike Friedrichs, Petra Heppner, Meret Lakner, Achim Ringeis
-
Patent number: 7732429Abstract: The present invention provides an improved methodology by which therapeutically to overcome resistance to tetracycline in living cells including bacteria, parasites, fungi, and rickettsiae. The methodology employs a blocking agent such as C5 ester derivatives, or 6-deoxy 13-(substituted mercapto) derivatives of tetracycline, in combination with other tetracycline-type antibiotics as a synergistic combination of compositions to be administered simultaneously, sequentially or concurrently. In another embodiment, certain novel compositions are provided which may be administered alone against, for example, a sensitive or resistant strain of gram positive bacteria such as S. aureus and E. faecalis. The concomitantly administered compositions effectively overcome the tetracycline resistant mechanisms present such that the cell is effectively converted from a tetracycline-resistant state to a tetracycline-sensitive state.Type: GrantFiled: August 19, 2008Date of Patent: June 8, 2010Assignee: Trustees of Tufts CollegeInventor: Stuart B. Levy